This analysis evaluated the safety and efficacy of nab-paclitaxel ( nab-P ) versus solvent-based paclitaxel ( sb-P ) , both in combination with carboplatin ( C ) , in patients with advanced non-small-cell lung cancer ( NSCLC ) and renal impairment .